William Blair Predicts Higher Earnings for Alto Neuroscience

Alto Neuroscience, Inc. (NYSE:ANRO) – William Blair lifted their FY2025 earnings estimates for Alto Neuroscience in a research report issued to clients and investors on Monday, October 20th. William Blair analyst M. Minter now expects that the company will earn ($2.31) per share for the year, up from their previous forecast of ($2.46). The consensus estimate for Alto Neuroscience’s current full-year earnings is ($2.54) per share. William Blair also issued estimates for Alto Neuroscience’s Q4 2025 earnings at ($0.53) EPS, Q1 2026 earnings at ($0.49) EPS, Q2 2026 earnings at ($0.49) EPS and FY2026 earnings at ($1.99) EPS.

Several other brokerages have also weighed in on ANRO. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Alto Neuroscience in a research report on Monday, August 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Alto Neuroscience in a research note on Wednesday, October 8th. Chardan Capital initiated coverage on shares of Alto Neuroscience in a research note on Monday, September 29th. They issued a “buy” rating and a $15.00 price target on the stock. Finally, Robert W. Baird raised their price target on shares of Alto Neuroscience from $10.00 to $16.00 and gave the company an “outperform” rating in a research note on Monday. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $11.00.

Alto Neuroscience Price Performance

Shares of NYSE ANRO opened at $10.22 on Thursday. Alto Neuroscience has a 1-year low of $1.60 and a 1-year high of $12.19. The company has a debt-to-equity ratio of 0.18, a current ratio of 18.43 and a quick ratio of 18.43. The business’s fifty day moving average price is $4.72 and its two-hundred day moving average price is $3.29. The firm has a market capitalization of $276.62 million, a PE ratio of -4.27 and a beta of 2.00.

Alto Neuroscience (NYSE:ANRO) last announced its quarterly earnings results on Wednesday, August 13th. The company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.08).

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in ANRO. Bank of Montreal Can acquired a new position in shares of Alto Neuroscience in the second quarter worth about $25,000. Ground Swell Capital LLC acquired a new stake in shares of Alto Neuroscience in the second quarter worth $27,000. Vanguard Personalized Indexing Management LLC acquired a new stake in Alto Neuroscience during the 2nd quarter worth about $33,000. AlphaCore Capital LLC boosted its position in Alto Neuroscience by 100.0% during the 2nd quarter. AlphaCore Capital LLC now owns 20,000 shares of the company’s stock worth $44,000 after acquiring an additional 10,000 shares during the period. Finally, AQR Capital Management LLC acquired a new stake in Alto Neuroscience during the 1st quarter worth about $52,000.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.